Processa announces presentation, publication of abstracts at ASCO meeting

Processa Pharmaceuticals (PCSA) announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa’s pipeline of Next Generation Cancer drug candidates, including PCS6422 and PCS11T, showcasing both preclinical and clinical advances. Trials in Progress Poster Presentation and Abstract Publication: Abstract Title: Adaptive Designed Eniluracil + Capecitabine Phase 2 Trial in Advanced or Metastatic Breast Cancer Patients: Dr. David Young, Founder and President of Research & Development at Processa, will be presenting an overview of Processa’s ongoing Phase 2 adaptive design trial evaluating the safety and efficacy of PCS6422 combined with capecitabine in patients with advanced or metastatic breast cancer. The study explores optimal dosing regimens and a personalized medicine approach to improve outcomes and tolerability. Abstract Publications: Abstract Title: Safety and Efficacy of Eniluracil + Capecitabine in Phase 1b Trial: This online-only abstract provides data from the Phase 1b study that defined the Maximum Tolerated Dose and Recommended Phase 2 Dose Range for NGC-Cap, highlighting its improved safety profile and anti-tumor activity compared to standard capecitabine. Abstract Title: Preclinical Project Optimus Dose Escalation of SN-38 Pro-Drug PCS11T: This online-only abstract outlines a Project Optimus-aligned approach to define the optimal therapeutic window of PCS11T, a tumor-targeted pro-drug of SN-38. PCS11T is designed to increase drug concentration in tumors while reducing systemic toxicity.